ClinicalTrials.gg
CompletedNCT03239522Updated Dec 3, 2019Results posted

Absorption and Elimination of Radiolabeled Daprodustat

A Phase 1 interventional study of [14C]-GSK1278863 solution for IV infusion and [14C]-GSK1278863 oral solution in Anaemia, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-03.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
30 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
28th of 30
6 · median 76
Started
2017
with 3 others
Phase 1
10 of 30
none open now
Registered
20th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 28th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 1, and was the 20th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 30 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

Absorption, metabolism and excretion of daprodustat (GSK1278863) have been studied in previous clinical trials; however, the elimination routes and metabolic pathways of daprodustat have not been fully elucidated in humans. This is an open-label, single-center, non-randomized, 2-period, single-sequence, crossover, mass balance study in 6 healthy male participants. The aim of the study is to assess the excretion balance of daprodustat using [14C]-radiolabeled drug substance administered orally, and as an intravenous (IV) infusion, administered as a microtracer dose (concomitant with an oral, non-radiolabeled dose). Absolute bioavailability of an oral dose will also be assessed. Each participant will be involved in the study for up to 10 weeks which include a screening visit, two treatment periods (treatment periods 1 and 2), separated by about 7 days (at least 14 days between oral doses), and a follow up visit 1-2 weeks after the last assessment in treatment period 2. The primary objective of the study is to gain a better understanding of the compound's excretory and metabolic profile. This study will include sampling of duodenal bile to conduct qualitative assessment of drug metabolites in this matrix in order to characterize biliary elimination pathways.

03

Conditions studied

  • Anaemia

Browse trials for

Keywords

  • GSK1278863
  • pharmacokinetics
  • mass balance
  • daprodustat
04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 30 to 55 years, inclusive, at the time of signing the .
  • Healthy, as determined by the investigator or medically qualified designee, based on a medical evaluation including medical history, physical examination, vital signs, laboratory tests, and . A participant with a clinical abnormality or laboratory parameter (i.e., outside the reference range for the population being studied), which is not specifically listed in the eligibility criteria, may be included only if the investigator agrees and documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • value at screening greater than the lower limit of the laboratory reference range and less than or equal to 16.0 gram (g) per deciliter (dL).
  • History of regular bowel movements (averaging one or more bowel movements per day).
  • Non-smoker, or ex-smoker who hasn't regularly smoked for the 6 months before screening.
  • Body weight of 50 kilogram (kg) and above, and (BMI) within the range 19.0-31 kg per meter (m)\^2 (inclusive).
  • Participants must agree to use as follows: participants with female partners of must agree to use a condom from the time of first dose of study treatment until 1 month after their last dose.
  • Capable of giving signed informed consent.
  • Willingness to give written consent to have data entered into The Over-volunteering Prevention System.

Exclusion criteria

Exclusion Criteria:

  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). Participants with a history of cholecystectomy must be excluded.
  • Any abnormality identified at the screening medical assessment (physical examination/medical history), clinical laboratory tests, or 12-lead .
  • Myocardial infarction or acute coronary syndrome \<=12 weeks prior to screening through to enrollment (Day 1, treatment period 1).
  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or which could constitute a risk when taking the study treatment, or interfere with the interpretation of data.
  • Evidence of actively bleeding gastric, duodenal or esophageal ulcer disease OR clinically significant GI bleeding \<=12 weeks prior to screening through to enrollment (Day 1, treatment period 1).
  • History of within the two years before dosing, with the exception of localized squamous cell or basal cell carcinoma of the skin that has been definitively treated prior to screening; currently receiving treatment for cancer; has a strong family history of cancer (e.g., familial cancer disorders).
  • Mentally or legally incapacitated.
  • Heart Failure: Class II, III or IV heart failure, as defined by the (NYHA) functional classification system.
  • Any other condition, clinical or laboratory abnormality, or examination finding that the investigator considers would put the participant at unacceptable risk, which may affect study compliance or prevent understanding of the aims or procedures or possible consequences of the study.
  • Daprodustat is a substrate of cytochrome P4502C8 (CYP2C8). Co-administration of drugs that are inhibitors of this enzyme are prohibited.
  • Past or intended use of over-the-counter or prescription medication including herbal medications prior to dosing except occasional use of paracetamol (acetaminophen), within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study treatment until completion of the follow-up visit, unless in the opinion of the investigator and GSK medical monitor the medication will not interfere with the study.
  • Current enrolment in a clinical trial; recent participation in a clinical trial and has received an investigational product within 3 months before their first dose in the current study.
  • Exposure to more than 4 new chemical entities within 12 months before their first dose in the current study.
  • Participation in a clinical trial involving administration of 14C-labelled compound(s) within the last 12 months. A participant's previous effective dose will be reviewed by the medical investigator to ensure there is no risk of contamination/carryover into the current study.
  • Received a total body radiation dose of greater than 10.0 millisievert (mSv) (upper limit of world health organization [WHO] category II) or exposure to significant radiation (e.g., serial x-ray or computed tomography [CT] scans, barium meal, etc.) in the 3 years before this study.
  • (ALT) >1.5 times (ULN).
  • >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • >500 millisecond (msec). The QTc must be the QTcB.
  • Presence of surface antigen (HBsAg) at screening or positive antibody test result at screening or within 3 months before the first dose of study treatment.
  • Positive pre-study drug/alcohol screen.
  • Positive (HIV) antibody test.
  • Regular use of known drugs of abuse.
  • Regular alcohol consumption within 6 months prior to the study defined as an average weekly intake of >21 units. One unit is equivalent to 8 g of alcohol: a glass (approximately 240 milliliter [mL]) of beer, 1 small glass (approximately 100 mL) of wine or 1 (approximately 25 mL) measure of spirits.
  • At screening, a supine blood pressure (BP) that is persistently higher than 140/90 millimeters of mercury (mmHg) taken in triplicate, unless deemed not clinically significant by the investigator.
  • At screening, a supine mean heart rate (HR) outside the range of 40-100 beats per minute, unless deemed not clinically significant by the investigator.
  • Has had an occupation which requires monitoring for radiation exposure, nuclear medicine procedures, or excessive x-rays within the past 12 months.
  • Unable to refrain from consumption of prohibited food and drinks from 7 days before the first dose of study medication until the follow up visit.
  • Participation in the study would result in donation of blood or blood products in excess of 550 mL within a 90 day period.
  • Unwillingness or inability to follow the procedures, including the use of the Entero-Test capsule.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products in the 6 months prior to screening.
  • History of drug abuse or dependence within 6 months of the study.
  • History of sensitivity to daprodustat, or their components thereof, or a history of drug or other allergy that, in the opinion of the investigator or GSK medical monitor, contraindicates their participation.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    All participants receiving treatment

    Each participant will receive a single 6 milligram (mg) oral dose of daprodustat on Day 1 of period 1. After approximately 1 hour, participants will receive 50 microgram (µg) of \[14C\]-GSK1278863 by IV infusion over 1 hour. On Day 1 of period 2, each participant will receive 25 mg \[14C\]-GSK1278863 as an oral solution.

    Drug: [14C]-GSK1278863 solution for IV infusion · Drug: [14C]-GSK1278863 oral solution · Drug: Daprodustat 6 mg oral tablet

Interventions

  • Drug[14C]-GSK1278863 solution for IV infusion

    It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of \[14C\]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.

  • It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of \[14C\]-GSK1278863 oral solution (total dose: 25 mg).

  • It is a 9.0 millimeter (mm) round, white film coated tablet.

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-Inf]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863

    Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population who had at least 1 non-missing pharmacokinetic assessment (Non-quantifiable \[NQ\] values were considered as non-missing values).

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  2. AUC (0-Inf) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863

    Blood samples were planned to be collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. Data were not analyzed for radiolabeled oral dose of GSK1278863 as there were not enough data points captured for a terminal slope required to calculate AUC (0-inf). The blood assay could not detect radiation levels at the time points blood was drawn to go into these calculations.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  3. AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863

    Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  4. AUC (0-t) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863

    Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  5. Maximum Observed Plasma Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863

    Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  6. Cmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863

    Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  7. Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863

    Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  8. Tmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863

    Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  9. Apparent Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863

    Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  10. T1/2 of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863

    Blood samples were planned to be collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. Data were not analyzed for radiolabeled oral dose of GSK1278863 as there were not enough data points captured for a terminal slope required to calculate t1/2. The blood assay could not detect radiation levels at the time points blood was drawn to go into these calculations.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  11. Volume of Distribution at Steady State (Vss) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863

    Plasma samples were collected from participants at indicated time points in treatment period 1, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1

  12. Vss of Total Drug-related Material (Radioactivity) in Blood Following IV Dose of GSK1278863

    Blood samples were planned to be collected from participants at indicated time points in treatment period 1, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1

  13. Total Systemic Clearance (CL) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863

    Plasma samples were collected from participants at indicated time points in treatment period 1 after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1

  14. CL of Total Drug-related Material (Radioactivity) in Blood Following IV Dose of GSK1278863

    Blood samples were planned to be collected from participants at indicated time points in treatment period 1 after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1

  15. Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863

    Urine samples were collected at the indicated time points to determine the rate and extent of excretion of total radioactivity in urine. All participants were asked to void their bladders before study treatment administration.

    Time frame: Pre-dose and then over 24 hours collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120,120-144 and 144-168 hours post-dose in treatment period 2

  16. Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863

    Fecal samples were collected at the indicated time points to determine the rate and extent of excretion of total radioactivity in feces.

    Time frame: Pre-dose and then over 24 hour collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 hours post-dose in treatment period 2

  17. Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time

    Urine and fecal samples were collected at the indicated time points to determine the rate and extent of cumulative excretion of total radioactivity in urine and feces.

    Time frame: Pre-dose and then over 24 hour collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 hours post-dose in treatment period 2

Secondary outcomes

  1. AUC (0-Inf) of GSK1278863 in Plasma Following Administration IV and Both Oral Doses

    Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  2. AUC(0-t) of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses

    Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  3. Cmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses

    Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  4. Tmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses

    Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  5. T1/2 of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses

    Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  6. AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses

    Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863.Pharmacokinetic analysis was conducted using standard non-compartmental methods. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  7. AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses

    Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  8. Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses

    Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  9. Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses

    Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  10. T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses

    Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

  11. Vss of GSK1278863 in Plasma Following IV Dose Administration

    Plasma samples were collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1

  12. Vss of GSK1278863 Metabolites in Plasma Following IV Dose Administration

    Plasma samples were planned to be collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1

  13. CL of GSK1278863 in Plasma Following IV Dose Administration

    Plasma samples were collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1

  14. CL of GSK1278863 Metabolites in Plasma Following IV Dose Administration

    Plasma samples were planned to be collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1

  15. Absolute Bioavailability of GSK1278863 Following Oral Dosing

    Absolute bioavailability is the amount of drug from a formulation that reaches the systemic circulation relative to an IV dose, computed as ratio of AUC(oral)/Dose(oral) with AUC(IV)/Dose(IV). Plasma samples were collected from participants at indicated time points. Absolute bioavailability from the oral tablet and IV doses administered in treatment period 1 was analyzed using AUC(0-inf) and AUC(0-t) pharmacokinetic parameters.

    Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1

  16. Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg

    Blood samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220) and M33 combined, M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. 2 pooled plasma samples were prepared. Aliquots of plasma samples collected between 0 to 8 hours post-dose from each participant were pooled in proportion to the time intervals. An equal amount of the individual pools from each participant was then pooled to create 1 plasma sample that was representative of the mean area under curve over the range of 0-8 hour. The second pool (10-12 hours pool) was obtained by mixing equal volume of the plasma samples at 10 and 12 hour across all participants. Percent radioactivity recovered for each metabolite in plasma following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.

    Time frame: 0-8 hours, 10-12 hours in period 2

  17. Percent Radioactivity Recovered for Each Metabolite in Urine Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg

    Urine samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220) and M33 combined, M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. One pooled urine sample was prepared by urine collected from 0 to 24 hours post dose from all participants. Percent radioactivity recovered for each metabolite in urine following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.

    Time frame: 0-24 hours in period 2

  18. Percent Radioactivity Recovered for Each Metabolite in Feces Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg

    Feces samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220), M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. One pooled feces sample was prepared by samples collected from 0 to 120 hours post dose from all participants. Percent radioactivity recovered for each metabolite in feces following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.

    Time frame: 0-120 hours in period 2

  19. Percent Radioactivity Recovered for Each Metabolite in Duodenal Bile Following a Single Dose of [14C]-GSK1278863 50 µg IV Infusion

    The bile string was swallowed by participants prior to oral dose and was removed 3 hours after the oral dose (1 hour after the end of the IV infusion) in treatment period-1. Duodenal bile string extracts were pooled to create a single pool sample to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single dose of \[14C\]-GSK1278863 50 µg IV infusion. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220), M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102). Mean percent radioactivity recovered for each metabolite in bile following a single dose of \[14C\]-GSK1278863 50 µg IV infusion is presented.

    Time frame: 3 hours post-oral dose in period 1

  20. Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life- threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per Medical or scientific judgment. Safety Population comprised of all participants who take at least 1 dose of study treatment. Participants were analyzed according to the treatment they actually received.

    Time frame: Up to 43 days

  21. Number of Participants With AEs at a Particular Severity

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity was categorized as mild, moderate and severe. The number of participants with AEs at any type of severity (mild, moderate and severe) has been presented.

    Time frame: Up to 43 days

  22. Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range

    Blood samples were collected from participants at indicated time points for the analysis of clinical chemistry parameters including Alanine Aminotransferase (ALT), Alkaline phosphatase (Alk Phos), Aspartate Aminotransferase (AST), Bilirubin, Calcium, Creatinine, Direct Bilirubin, Glucose, Potassium, Protein, Sodium and Urea. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (example given \[e.g.\], High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.

    Time frame: Up to 43 days

  23. Number of Participants With Worst Case Hematology Results Relative to Normal Range

    Blood samples were collected from participants at indicated time points for the analysis of hematology parameters including Basophils, Eosinophils, Erythrocyte Mean Corpuscular Hemoglobin (MCH), Erythrocyte Mean Corpuscular Volume (MCV), Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets, Reticulocytes, and Reticulocytes/Erythrocytes. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.

    Time frame: Up to 43 days

  24. Number of Participants With Abnormal Urinalysis Findings

    Urine samples were collected at indicated time points for the analysis of urinalysis parameters including specific gravity and PH of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase in urine.

    Time frame: Up to 43 days

  25. Number of Participants With Abnormal Electrocardiogram (ECG) Findings

    Full 12-lead ECGs were recorded with the participant in a supine position. The number of participants with abnormal ECG findings at indicated time points were presented. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.

    Time frame: Pre-dose (on Day 1) and Day 8 in treatment period 2; 144 hours (Day 7) in treatment period 1

  26. Change From Baseline in Blood Pressure

    Vital sign including systolic and diastolic blood pressure were measured in a semi-supine position after 5 minutes rest. Baseline is defined as the mean of the 3 pre-dose measurements (Average \[Avg\] Pre-dose) taken on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.

    Time frame: Baseline (average of Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2

  27. Change From Baseline in Heart Rate

    Heart rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the mean of the 3 pre-dose measurements (Avg Pre-dose) taken on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.

    Time frame: Baseline (average of Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2

  28. Change From Baseline in Respiratory Rate

    Respiratory rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the pre-dose on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.

    Time frame: Baseline (Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2

  29. Change From Baseline in Body Temperature

    Body temperature measurement was performed in participants at indicated time points. Baseline is defined as the pre-dose on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.

    Time frame: Baseline (Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2

07

Results

Posted Mar 18, 2019

Participant flow

This study evaluated the excretion balance of daprodustat(GSK1278863) using radiolabeled 14 Carbon \[14C\]-drug substance administered orally, and as an intravenous (IV) infusion, administered as a micro tracer dose (concomitant with an oral, non-radiolabeled dose) in healthy male participants.

Treatment Period 1 (Up to 7 Days)
Participant flow — Treatment Period 1 (Up to 7 Days)
MilestoneAll Participants Receiving GSK1278863
Started6
Completed6
Not completed0
Washout Period (Up to 7 Days)
Participant flow — Washout Period (Up to 7 Days)
MilestoneAll Participants Receiving GSK1278863
Started6
Completed6
Not completed0
Treatment Period 2 (Up to 15 Days)
Participant flow — Treatment Period 2 (Up to 15 Days)
MilestoneAll Participants Receiving GSK1278863
Started6
Completed6
Not completed0

Outcome measures

PrimaryArea Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-Inf]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863

Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population who had at least 1 non-missing pharmacokinetic assessment (Non-quantifiable \[NQ\] values were considered as non-missing values).

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Hour*nanogram equivalent per milliliter
Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-Inf]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Hour*nanogram equivalent per milliliter[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-Inf]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK12788636.6864 ± 19.82278.8914 ± 18.2
PrimaryAUC (0-Inf) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863

Blood samples were planned to be collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. Data were not analyzed for radiolabeled oral dose of GSK1278863 as there were not enough data points captured for a terminal slope required to calculate AUC (0-inf). The blood assay could not detect radiation levels at the time points blood was drawn to go into these calculations.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

No measurements were reported for this outcome.

PrimaryAUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863

Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Hour*nanogram equivalent per milliliter
AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Hour*nanogram equivalent per milliliter[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK12788636.5252 ± 18.92206.7099 ± 18.5
PrimaryAUC (0-t) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863

Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Hour*nanogram equivalent per milliliter
AUC (0-t) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863
Hour*nanogram equivalent per milliliter[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
AUC (0-t) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863—824.6102 ± 17.2
PrimaryMaximum Observed Plasma Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863

Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Nanogram equivalent per milliliter
Maximum Observed Plasma Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Nanogram equivalent per milliliter[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Maximum Observed Plasma Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK12788633.0114 ± 15.8623.9059 ± 34.8
PrimaryCmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863

Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Nanogram equivalent per milliliter
Cmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863
Nanogram equivalent per milliliter[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Cmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863—289.9998 ± 30.7
PrimaryTime of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863

Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Median · Hour
Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Hour[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK12788630.9833 (0.983 to 1.250)0.7583 (0.500 to 3.000)
PrimaryTmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863

Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Median · Hour
Tmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863
Hour[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Tmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863—1.0000 (1.000 to 3.000)
PrimaryApparent Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863

Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Hour
Apparent Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Hour[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Apparent Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK12788636.7699 ± 106.461.8251 ± 15.1
PrimaryT1/2 of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863

Blood samples were planned to be collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. Data were not analyzed for radiolabeled oral dose of GSK1278863 as there were not enough data points captured for a terminal slope required to calculate t1/2. The blood assay could not detect radiation levels at the time points blood was drawn to go into these calculations.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2

No measurements were reported for this outcome.

PrimaryVolume of Distribution at Steady State (Vss) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863

Plasma samples were collected from participants at indicated time points in treatment period 1, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Reported as:
Geometric mean · Liters
Volume of Distribution at Steady State (Vss) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863
Liters[14C]-GSK1278863 50 µg IV Infusion
Volume of Distribution at Steady State (Vss) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK127886332.2355 ± 59.1
PrimaryVss of Total Drug-related Material (Radioactivity) in Blood Following IV Dose of GSK1278863

Blood samples were planned to be collected from participants at indicated time points in treatment period 1, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1

No measurements were reported for this outcome.

PrimaryTotal Systemic Clearance (CL) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863

Plasma samples were collected from participants at indicated time points in treatment period 1 after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Reported as:
Geometric mean · Liters per hour
Total Systemic Clearance (CL) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863
Liters per hour[14C]-GSK1278863 50 µg IV Infusion
Total Systemic Clearance (CL) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK12788637.4779 ± 19.8
PrimaryCL of Total Drug-related Material (Radioactivity) in Blood Following IV Dose of GSK1278863

Blood samples were planned to be collected from participants at indicated time points in treatment period 1 after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1

No measurements were reported for this outcome.

PrimaryPercentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863

Urine samples were collected at the indicated time points to determine the rate and extent of excretion of total radioactivity in urine. All participants were asked to void their bladders before study treatment administration.

Time frame:
Pre-dose and then over 24 hours collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120,120-144 and 144-168 hours post-dose in treatment period 2
Reported as:
Mean · Percent dose excreted
Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863
Percent dose excreted[14C]-GSK1278863 25 mg Oral Solution
Pre-dose; n=60.000 ± 0.0000
0-24 hours; n=620.450 ± 2.7441
24-48 hours; n=620.838 ± 2.8280
48-72 hours; n=621.003 ± 2.8723
72-96 hours; n=621.065 ± 2.8744
96-120 hours; n=621.065 ± 2.8744
120-144 hours; n=621.065 ± 2.8744
144-168 hours; n=521.434 ± 3.0507
PrimaryPercentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863

Fecal samples were collected at the indicated time points to determine the rate and extent of excretion of total radioactivity in feces.

Time frame:
Pre-dose and then over 24 hour collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 hours post-dose in treatment period 2
Reported as:
Mean · Percent dose excreted
Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863
Percent dose excreted[14C]-GSK1278863 25 mg Oral Solution
Pre-dose; n=60.000 ± 0.0000
0-24 hours; n=50.096 ± 0.1292
24-48 hours; n=522.298 ± 31.0164
48-72 hours; n=649.988 ± 25.3857
72-96 hours; n=668.312 ± 6.0872
96-120 hours; n=573.450 ± 3.1046
120-144 hours; n=574.698 ± 2.1027
144-168 hours; n=473.553 ± 3.6611
PrimaryPercentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time

Urine and fecal samples were collected at the indicated time points to determine the rate and extent of cumulative excretion of total radioactivity in urine and feces.

Time frame:
Pre-dose and then over 24 hour collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 hours post-dose in treatment period 2
Reported as:
Mean · Percent dose excreted
Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time
Percent dose excreted[14C]-GSK1278863 25 mg Oral Solution
Pre-dose; n=60.000 ± 0.0000
0-24 hours; n=620.530 ± 2.7223
24-48 hours; n=639.433 ± 28.2968
48-72 hours; n=670.992 ± 25.9980
72-96 hours; n=689.377 ± 6.3351
96-120 hours; n=694.177 ± 2.1428
120-144 hours; n=694.705 ± 2.0982
144-168 hours; n=594.582 ± 2.3066
SecondaryAUC (0-Inf) of GSK1278863 in Plasma Following Administration IV and Both Oral Doses

Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Hour*nanogram per milliliter
AUC (0-Inf) of GSK1278863 in Plasma Following Administration IV and Both Oral Doses
Hour*nanogram per milliliterGSK1278863 6 mg Oral Tablet[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
AUC (0-Inf) of GSK1278863 in Plasma Following Administration IV and Both Oral Doses199.2552 ± 16.92.6509 ± 27.4940.2011 ± 28.6
SecondaryAUC(0-t) of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses

Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Hour*nanogram per milliliter
AUC(0-t) of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses
Hour*nanogram per milliliterGSK1278863 6 mg Oral Tablet[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
AUC(0-t) of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses198.1658 ± 16.82.6368 ± 20.4938.5541 ± 28.7
SecondaryCmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses

Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Nanogram per milliliter
Cmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses
Nanogram per milliliterGSK1278863 6 mg Oral Tablet[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Cmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses96.1190 ± 17.22.0058 ± 25.5544.7022 ± 34.1
SecondaryTmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses

Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Median · Hour
Tmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses
HourGSK1278863 6 mg Oral Tablet[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Tmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses2.1167 (1.417 to 4.000)0.983 (0.983 to 0.983)0.5000 (0.500 to 0.517)
SecondaryT1/2 of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses

Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Hour
T1/2 of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses
HourGSK1278863 6 mg Oral Tablet[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
T1/2 of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses1.8786 ± 21.62.0653 ± 6.62.5037 ± 30.2
SecondaryAUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses

Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863.Pharmacokinetic analysis was conducted using standard non-compartmental methods. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Hour*nanogram per milliliter
AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
Hour*nanogram per milliliterGSK1278863 6 mg Oral Tablet[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
GSK2391220; n=6,0,533.7699 ± 15.1—139.7713 ± 19.0
GSK2487818; n=6,0,621.7209 ± 16.3—92.0554 ± 16.7
GSK2506102; n=6,0,68.6207 ± 15.5—33.1332 ± 15.6
GSK2506104; n=6,0,534.1180 ± 11.9—140.3785 ± 16.7
GSK2531398; n=6,0,615.0285 ± 13.1—61.7760 ± 15.4
GSK2531401; n=6,0,634.4699 ± 21.9—124.1320 ± 25.5
SecondaryAUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses

Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Hour*nanogram per milliliter
AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
Hour*nanogram per milliliterGSK1278863 6 mg Oral Tablet[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
GSK239122032.2574 ± 15.0—142.2907 ± 18.9
GSK248781821.2933 ± 16.8—90.9953 ± 16.7
GSK25061028.0798 ± 14.1—31.8897 ± 15.9
GSK250610432.3120 ± 11.9—142.3372 ± 15.6
GSK253139814.4743 ± 13.4—60.2615 ± 15.5
GSK253140131.7836 ± 18.8—122.7102 ± 25.8
SecondaryCmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses

Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Nanogram per milliliter
Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
Nanogram per milliliterGSK1278863 6 mg Oral Tablet[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
GSK23912207.5219 ± 14.4—31.5278 ± 30.4
GSK24878186.0391 ± 19.1—25.4542 ± 33.0
GSK25061021.8233 ± 16.6—6.8139 ± 25.7
GSK25061047.3607 ± 13.5—30.4258 ± 27.6
GSK25313983.5279 ± 12.7—13.5590 ± 25.8
GSK25314016.4247 ± 23.6—21.9493 ± 36.8
SecondaryTmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses

Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Median · Hour
Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
HourGSK1278863 6 mg Oral Tablet[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
GSK23912203.5000 (2.983 to 6.000)—2.0000 (1.500 to 4.000)
GSK24878183.5000 (1.983 to 6.000)—2.0000 (1.500 to 4.000)
GSK25061023.5000 (2.983 to 6.000)—2.0000 (2.000 to 4.000)
GSK25061044.0000 (2.983 to 6.000)—2.0000 (2.000 to 4.000)
GSK25313983.5000 (2.983 to 6.000)—2.0000 (2.000 to 4.000)
GSK25314014.0000 (3.000 to 6.000)—2.0000 (2.000 to 4.000)
SecondaryT1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses

Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Reported as:
Geometric mean · Hour
T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
HourGSK1278863 6 mg Oral Tablet[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
GSK2391220; n=6,0, 51.9805 ± 7.9—3.1506 ± 26.1
GSK2487818; n=6,0, 61.5744 ± 12.5—1.8644 ± 10.7
GSK2506102; n=6,0, 62.0037 ± 15.9—2.2738 ± 5.1
GSK2506104; n=6,0, 52.0849 ± 8.0—3.3870 ± 10.9
GSK2531398; n=6,0, 61.7006 ± 14.7—1.9767 ± 3.8
GSK2531401; n=6,0, 62.3217 ± 12.0—2.9197 ± 9.9
SecondaryVss of GSK1278863 in Plasma Following IV Dose Administration

Plasma samples were collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Reported as:
Geometric mean · Liter
Vss of GSK1278863 in Plasma Following IV Dose Administration
Liter[14C]-GSK1278863 50 µg IV Infusion
Vss of GSK1278863 in Plasma Following IV Dose Administration14.3387 ± 23.0
SecondaryVss of GSK1278863 Metabolites in Plasma Following IV Dose Administration

Plasma samples were planned to be collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1

No measurements were reported for this outcome.

SecondaryCL of GSK1278863 in Plasma Following IV Dose Administration

Plasma samples were collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Reported as:
Geometric mean · Liter per hour
CL of GSK1278863 in Plasma Following IV Dose Administration
Liter per hour[14C]-GSK1278863 50 µg IV Infusion
CL of GSK1278863 in Plasma Following IV Dose Administration18.8612 ± 27.4
SecondaryCL of GSK1278863 Metabolites in Plasma Following IV Dose Administration

Plasma samples were planned to be collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1

No measurements were reported for this outcome.

SecondaryAbsolute Bioavailability of GSK1278863 Following Oral Dosing

Absolute bioavailability is the amount of drug from a formulation that reaches the systemic circulation relative to an IV dose, computed as ratio of AUC(oral)/Dose(oral) with AUC(IV)/Dose(IV). Plasma samples were collected from participants at indicated time points. Absolute bioavailability from the oral tablet and IV doses administered in treatment period 1 was analyzed using AUC(0-inf) and AUC(0-t) pharmacokinetic parameters.

Time frame:
Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Reported as:
Geometric mean · Ratio of dose normalized AUC
Absolute Bioavailability of GSK1278863 Following Oral Dosing
Ratio of dose normalized AUCGSK1278863 6 mg Oral Tablet
AUC (0-inf); n=30.6575 ± 11.8
AUC (0-t); n=60.6263 ± 10.7
SecondaryPercent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg

Blood samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220) and M33 combined, M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. 2 pooled plasma samples were prepared. Aliquots of plasma samples collected between 0 to 8 hours post-dose from each participant were pooled in proportion to the time intervals. An equal amount of the individual pools from each participant was then pooled to create 1 plasma sample that was representative of the mean area under curve over the range of 0-8 hour. The second pool (10-12 hours pool) was obtained by mixing equal volume of the plasma samples at 10 and 12 hour across all participants. Percent radioactivity recovered for each metabolite in plasma following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.

Time frame:
0-8 hours, 10-12 hours in period 2
Reported as:
Number · Percent radioactivity
Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg
Percent radioactivity[14C]-GSK1278863 25 mg Oral Solution
M2 (GSK2391220) and M33 combined, 0-8 hours10.4
M2 (GSK2391220) and M33 combined, 10-12 hours14.4
M3 (GSK2506104), 0-8 hours7.6
M3 (GSK2506104), 10-12 hours11.8
M4 (GSK2487818), 0-8 hours5.7
M4 (GSK2487818), 10-12 hoursNA
M6 (GSK2531398), 0-8 hours3.6
M6 (GSK2531398), 10-12 hoursNA
M13 (GSK2531401), 0-8 hours8.3
M13 (GSK2531401), 10-12 hours16.1
M5 (GSK2506102) and M14 combined, 0-8 hours4.5
M5 (GSK2506102) and M14 combined, 10-12 hoursNA
SecondaryPercent Radioactivity Recovered for Each Metabolite in Urine Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg

Urine samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220) and M33 combined, M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. One pooled urine sample was prepared by urine collected from 0 to 24 hours post dose from all participants. Percent radioactivity recovered for each metabolite in urine following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.

Time frame:
0-24 hours in period 2
Reported as:
Number · Percent radioactivity
Percent Radioactivity Recovered for Each Metabolite in Urine Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg
Percent radioactivity[14C]-GSK1278863 25 mg Oral Solution
M2 (GSK2391220) and M33 combined15.8
M3 (GSK2506104)16.0
M4 (GSK2487818)7.9
M6 (GSK2531398)5.8
M13 (GSK2531401)16.5
M5 (GSK2506102) and M14 combined10.4
SecondaryPercent Radioactivity Recovered for Each Metabolite in Feces Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg

Feces samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220), M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. One pooled feces sample was prepared by samples collected from 0 to 120 hours post dose from all participants. Percent radioactivity recovered for each metabolite in feces following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.

Time frame:
0-120 hours in period 2
Reported as:
Number · Percent radioactivity
Percent Radioactivity Recovered for Each Metabolite in Feces Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg
Percent radioactivity[14C]-GSK1278863 25 mg Oral Solution
M2 (GSK2391220)19.8
M3 (GSK2506104)14.1
M4 (GSK2487818)17.0
M6 (GSK2531398)6.2
M13 (GSK2531401)4.9
M5 (GSK2506102) and M14 combined7.7
SecondaryPercent Radioactivity Recovered for Each Metabolite in Duodenal Bile Following a Single Dose of [14C]-GSK1278863 50 µg IV Infusion

The bile string was swallowed by participants prior to oral dose and was removed 3 hours after the oral dose (1 hour after the end of the IV infusion) in treatment period-1. Duodenal bile string extracts were pooled to create a single pool sample to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single dose of \[14C\]-GSK1278863 50 µg IV infusion. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220), M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102). Mean percent radioactivity recovered for each metabolite in bile following a single dose of \[14C\]-GSK1278863 50 µg IV infusion is presented.

Time frame:
3 hours post-oral dose in period 1
Reported as:
Number · Percent radioactivity
Percent Radioactivity Recovered for Each Metabolite in Duodenal Bile Following a Single Dose of [14C]-GSK1278863 50 µg IV Infusion
Percent radioactivity[14C]-GSK1278863 50 µg IV Infusion
M2 (GSK2391220)12.3
M3 (GSK2506104)20.0
M4 (GSK2487818)15.5
M6 (GSK2531398)6.3
M13 (GSK2531401)2.4
M511.1
SecondaryNumber of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life- threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per Medical or scientific judgment. Safety Population comprised of all participants who take at least 1 dose of study treatment. Participants were analyzed according to the treatment they actually received.

Time frame:
Up to 43 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
ParticipantsGSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Any AE22
Any SAE00
SecondaryNumber of Participants With AEs at a Particular Severity

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity was categorized as mild, moderate and severe. The number of participants with AEs at any type of severity (mild, moderate and severe) has been presented.

Time frame:
Up to 43 days
Reported as:
Count of participants · Participants
Number of Participants With AEs at a Particular Severity
ParticipantsGSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Mild22
Moderate10
Severe00
SecondaryNumber of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range

Blood samples were collected from participants at indicated time points for the analysis of clinical chemistry parameters including Alanine Aminotransferase (ALT), Alkaline phosphatase (Alk Phos), Aspartate Aminotransferase (AST), Bilirubin, Calcium, Creatinine, Direct Bilirubin, Glucose, Potassium, Protein, Sodium and Urea. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (example given \[e.g.\], High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.

Time frame:
Up to 43 days
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range
ParticipantsGSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
ALT; To Low00
ALT;To Normal or No Change66
ALT; To High00
Alk Phos; To Low00
Alk Phos; To Normal or No Change66
Alk Phos; To High00
AST; To Low00
AST;To Normal or No Change66
AST; To High00
Bilirubin; To Low00
Bilirubin; To Normal or No Change56
Bilirubin; To High11
Calcium; To Low00
Calcium; To Normal or No Change66
Calcium; To High00
Creatinine; To Low00
Creatinine; To Normal or No Change66
Creatinine; To High00
Direct Bilirubin; To Low00
Direct Bilirubin; To Normal or No Change66
Direct Bilirubin; To High00
Glucose; To Low00
Glucose; To Normal or No Change66
Glucose; To High00
Potassium; To Low00
Potassium; To Normal or No Change66
Potassium; To High00
Protein; To Low00
Protein; To Normal or No Change66
Protein; To High00
Sodium; To Low10
Sodium; To Normal or No Change56
Sodium; To High00
Urea; To Low00
Urea;To Normal or No Change66
Urea; To High00
SecondaryNumber of Participants With Worst Case Hematology Results Relative to Normal Range

Blood samples were collected from participants at indicated time points for the analysis of hematology parameters including Basophils, Eosinophils, Erythrocyte Mean Corpuscular Hemoglobin (MCH), Erythrocyte Mean Corpuscular Volume (MCV), Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets, Reticulocytes, and Reticulocytes/Erythrocytes. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.

Time frame:
Up to 43 days
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Hematology Results Relative to Normal Range
ParticipantsGSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Basophils; To Low00
Basophils; To Normal or No Change66
Basophils; To High00
Eosinophils; To Low00
Eosinophils; To Normal or No Change66
Eosinophils; To High00
MCH; To Low00
MCH; To Normal or No Change66
MCH; To High00
MCV; To Low00
MCV; To Normal or No Change66
MCV; To High00
Erythrocytes; To Low10
Erythrocytes; To Normal or No Change56
Erythrocytes; To High00
Hematocrit; To Low11
Hematocrit; To Normal or No Change55
Hematocrit; To High00
Hemoglobin; To Low10
Hemoglobin; To Normal or No Change56
Hemoglobin; To High00
Leukocytes; To Low00
Leukocytes; To Normal or No Change66
Leukocytes; To High00
Lymphocytes; To Low10
Lymphocytes; To Normal or No Change56
Lymphocytes; To High00
Monocytes; To Low00
Monocytes; To Normal or No Change66
Monocytes; To High00
Neutrophils; To Low00
Neutrophils; To Normal or No Change66
Neutrophils; To High00
Platelets; To Low00
Platelets; To Normal or No Change66
Platelets; To High00
Reticulocytes; To Low00
Reticulocytes; To Normal or No Change66
Reticulocytes; To High01
Reticulocytes/Erythrocytes; To Low00
Reticulocytes/Erythrocytes; To Normal or No Change65
Reticulocytes/Erythrocytes; To High02
SecondaryNumber of Participants With Abnormal Urinalysis Findings

Urine samples were collected at indicated time points for the analysis of urinalysis parameters including specific gravity and PH of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase in urine.

Time frame:
Up to 43 days
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Urinalysis Findings
ParticipantsGSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Number of Participants With Abnormal Urinalysis Findings00
SecondaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings

Full 12-lead ECGs were recorded with the participant in a supine position. The number of participants with abnormal ECG findings at indicated time points were presented. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.

Time frame:
Pre-dose (on Day 1) and Day 8 in treatment period 2; 144 hours (Day 7) in treatment period 1
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
ParticipantsGSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Pre-dose (Day 1); n=0,6—0
144 hours (Day 7); n= 6, 00—
Day 8; n=0, 6—0
SecondaryChange From Baseline in Blood Pressure

Vital sign including systolic and diastolic blood pressure were measured in a semi-supine position after 5 minutes rest. Baseline is defined as the mean of the 3 pre-dose measurements (Average \[Avg\] Pre-dose) taken on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.

Time frame:
Baseline (average of Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2
Reported as:
Mean · Millimeters of mercury
Change From Baseline in Blood Pressure
Millimeters of mercuryGSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
SBP; Avg 3 hours; n=6, 6-0.17 ± 5.722-1.22 ± 3.468
SBP; Avg 144 hours (Day 7); n=6, 65.06 ± 10.521-2.00 ± 9.541
SBP; Avg Day 8; n=0,6—4.22 ± 4.075
DBP; Avg 3 hours; n=6, 61.22 ± 5.4840.89 ± 4.834
DBP; Avg 144 hours (Day 7); n=6, 63.61 ± 9.365-1.00 ± 9.814
DBP; Avg Day 8; n=0,6—3.39 ± 5.170
SecondaryChange From Baseline in Heart Rate

Heart rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the mean of the 3 pre-dose measurements (Avg Pre-dose) taken on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.

Time frame:
Baseline (average of Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2
Reported as:
Mean · Beats per minute
Change From Baseline in Heart Rate
Beats per minuteGSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
Avg 3 hours; n=6, 60.22 ± 3.5261.67 ± 3.425
Avg 144 hours (Day 7); n=6, 61.28 ± 6.5713.78 ± 5.500
Avg Day 8; n=0,6—4.72 ± 5.535
SecondaryChange From Baseline in Respiratory Rate

Respiratory rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the pre-dose on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.

Time frame:
Baseline (Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2
Reported as:
Mean · Breaths per minute
Change From Baseline in Respiratory Rate
Breaths per minuteGSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
3 hours; n=6, 6-0.67 ± 2.422-0.33 ± 4.082
144 hours (Day 7); n=6, 6-1.33 ± 2.066-0.33 ± 1.506
Day 8; n=0,6—0.00 ± 2.530
SecondaryChange From Baseline in Body Temperature

Body temperature measurement was performed in participants at indicated time points. Baseline is defined as the pre-dose on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.

Time frame:
Baseline (Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2
Reported as:
Mean · Celsius
Change From Baseline in Body Temperature
CelsiusGSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
3 hours; n=6, 60.08 ± 0.1830.25 ± 0.455
144 hours (Day 7); n=6, 60.07 ± 0.4460.12 ± 0.588
Day 8; n=0,6—0.30 ± 0.693

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected from the start of the study treatment up to 43 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion0/6 (0%)0/6 (0%)2/6 (33.3%)
[14C]-GSK1278863 25 mg Oral Solution0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Most frequent other events
EventGSK1278863 6 mg Oral Tablet+[14C]-GSK1278863 50 µg IV Infusion[14C]-GSK1278863 25 mg Oral Solution
HeadacheNervous system disorders1/61/6
Back painMusculoskeletal and connective tissue disorders1/60/6
Decreased appetiteMetabolism and nutrition disorders1/60/6
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/61/6
MyalgiaMusculoskeletal and connective tissue disorders1/60/6
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/61/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Participants Receiving GSK1278863
Mean40.7 ± 8.57
Sex: Female, Male
Sex: Female, Male(Participants)All Participants Receiving GSK1278863
Female0
Male6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants Receiving GSK1278863
WHITE - ARABIC/NORTH AFRICAN HERITAGE1
WHITE - WHITE/CAUCASIAN/EUROPEAN HERITAGE5
08

Study locations

1 site
  • GSK Investigational Site
    London, NW10 7EW, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Nov 2017, 1 month.

Results were first posted in Mar 2019, 1 year 3 months after primary completion.

Of 34 industry-sponsored phase 1 interventional studies under Anemia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 30. This study's 1 month is below that.

Counting every sponsor, half of 48 studies reached it within 12 months; a quarter within 3 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2017
First posted
Aug 4, 2017
StartActual
Oct 10, 2017
Primary completionActual
Nov 28, 2017
CompletionActual
Nov 28, 2017
Results first posted
Mar 18, 2019
Last update
Dec 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03239522
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 4, 2017
Start date
Oct 10, 2017
Primary completion
Nov 28, 2017
Completion
Nov 28, 2017
Results posted
Mar 18, 2019
Last update
Dec 3, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion